Brigham and Women's Hospital: Multiple Sclerosis trials

The registry lists 14 Multiple Sclerosis studies with Brigham and Women's Hospital as lead sponsor. 4 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 4Phase 2 4Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Glucose Consumption in MS Using [F-18]FDG-PETRecruitingNCT07087106Phase 4
• Assessment of Synaptic Density in MSRecruitingNCT04634994Early Phase 1
• Molecular Imaging of NET Using [C-11]MRB-PET in MSRecruitingNCT03207464Phase 1/2
• PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesRecruitingNCT02649985Phase 1/2
• Self-Directed Positive Psychology Intervention for Newly Diagnosed Multiple SclerosisCompletedNCT06891937Not applicableResults posted
• Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related FatigueCompletedNCT04144257Phase 1/2Results posted
• A Positive Psychology Intervention for Patients With Multiple SclerosisCompletedNCT03637699Not applicableResults posted
• Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis PatientsTerminatedNCT05319093
• Ocrelizumab Access by Socio-Economic StatusCompletedNCT05131984
• COVID-19 Vaccine Response in Treated MS PatientsCompletedNCT05060354
• Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple SclerosisWithdrawnNCT03983252Phase 1/2
• PREG-MS: New England MS Pregnancy RegistryCompletedNCT03368157
• Immune Profiling During Ocrelizumab Treatment in Multiple SclerosisCompletedNCT03138525
• Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MSWithdrawnNCT02419638